Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G D Pollock

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Cardiovascular Pharmacology|April 1, 1987
Pharmacology of LY195115, a potent, orally active cardiotonic with a long duration of actionJ S Hayes, G D Pollock, H Wilson, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1985
Pharmacology of LY175326: a potent cardiotonic agent with vasodilator activitiesJ S Hayes, G D Pollock, H Wilson, et al.
Circulation Research|September 1, 1977
The effect of dobutamine on cardiac oxygen balance, regional blood flow, and infarction severity after coronary artery narrowing in dogsR R Tuttle, G D Pollock, G Todd, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1981
Alpha and beta adrenergic effects of the stereoisomers of dobutamineR R Ruffolo, T A Spradlin, G D Pollock, et al.
Analytical Biochemistry|September 1, 1975
A method for counting six gamma nuclides simultaneously in a three channel counterH W Culp, W D Daniels, D J Pieper, et al.
Journal of Medicinal Chemistry|May 1, 1987
Dihydropyridazinone cardiotonics: synthesis and inotropic activity of 5'-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)spiro[cycloalkane- 1,3'-[3H]indol]-2'(1'H)-onesD W Robertson, J H Krushinski, G D Pollock, et al.
Journal of Medicinal Chemistry|April 1, 1987
Molecular structure of the dihydropyridazinone cardiotonic 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-pyridazinyl)- 2H-indol-2-one, a potent inhibitor of cyclic AMP phosphodiesteraseD W Robertson, N D Jones, J H Krushinski, et al.
Journal of Medicinal Chemistry|June 1, 1985
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridineD W Robertson, E E Beedle, J H Krushinski, et al.
Journal of Medicinal Chemistry|October 1, 1986
Dihydropyridazinone cardiotonics: the discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H -indol-2- oneD W Robertson, J H Krushinski, E E Beedle, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Cardiovascular Pharmacology|April 1, 1987
Pharmacology of LY195115, a potent, orally active cardiotonic with a long duration of actionJ S Hayes, G D Pollock, H Wilson, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1985
Pharmacology of LY175326: a potent cardiotonic agent with vasodilator activitiesJ S Hayes, G D Pollock, H Wilson, et al.
Circulation Research|September 1, 1977
The effect of dobutamine on cardiac oxygen balance, regional blood flow, and infarction severity after coronary artery narrowing in dogsR R Tuttle, G D Pollock, G Todd, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1981
Alpha and beta adrenergic effects of the stereoisomers of dobutamineR R Ruffolo, T A Spradlin, G D Pollock, et al.
Analytical Biochemistry|September 1, 1975
A method for counting six gamma nuclides simultaneously in a three channel counterH W Culp, W D Daniels, D J Pieper, et al.
Journal of Medicinal Chemistry|May 1, 1987
Dihydropyridazinone cardiotonics: synthesis and inotropic activity of 5'-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)spiro[cycloalkane- 1,3'-[3H]indol]-2'(1'H)-onesD W Robertson, J H Krushinski, G D Pollock, et al.
Journal of Medicinal Chemistry|April 1, 1987
Molecular structure of the dihydropyridazinone cardiotonic 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-pyridazinyl)- 2H-indol-2-one, a potent inhibitor of cyclic AMP phosphodiesteraseD W Robertson, N D Jones, J H Krushinski, et al.
Journal of Medicinal Chemistry|June 1, 1985
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridineD W Robertson, E E Beedle, J H Krushinski, et al.
Journal of Medicinal Chemistry|October 1, 1986
Dihydropyridazinone cardiotonics: the discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H -indol-2- oneD W Robertson, J H Krushinski, E E Beedle, et al.
Pageof 2